- Home
- KPRX vs BYAH Comparison
KPRX vs BYAH Comparison
Compare KPRX & BYAH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KPRX | BYAH |
|---|---|---|
| Founded | 1998 | 2016 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Package Goods/Cosmetics |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 10.8M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | KPRX | BYAH |
|---|---|---|
| Price | $2.05 | $0.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | 51.8K | ★ 230.4K |
| Earning Date | 11-07-2025 | 08-26-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $2,768,120.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 42.65 |
| 52 Week Low | $1.77 | $0.20 |
| 52 Week High | $4.18 | $41.49 |
Technical Indicators
Market Signals| Indicator | KPRX | BYAH |
|---|---|---|
| Relative Strength Index (RSI) | 45.01 | N/A |
| Support Level | $1.80 | N/A |
| Resistance Level | $2.17 | N/A |
| Average True Range (ATR) | 0.14 | 0.00 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 59.60 | 0.00 |
Price Performance
Historical ComparisonAbout KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About BYAH Park Ha Biological Technology Co. Ltd. Ordinary Shares
Park Ha Biological Technology Co Ltd is engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions. Its Park Ha brand focuses on providing solutions for problematic skin. The company's Operating Subsidiaries provide skincare and cosmetic products under its brand, Park Ha in China. Its Operating Subsidiaries develop its proprietary beauty products and offer complimentary after-sales beauty services in its physical stores.